Skip to main content
Pharmaron Beijing Co., Ltd logo

Pharmaron Beijing Co., Ltd — Investor Relations & Filings

Ticker · 3759 ISIN · CNE100003PG4 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 991 across all filing types
Latest filing 2024-06-17 Regulatory Filings
Country HK Hong Kong
Listing HKEX 3759

About Pharmaron Beijing Co., Ltd

http://www.pharmaron.com

Pharmaron is a premier life science service provider and a comprehensive Contract Research and Manufacturing Organization (CRO/CDMO). The company delivers integrated research, development, and manufacturing capabilities across the entire drug development continuum, encompassing discovery, preclinical testing, clinical trials, and commercialization. Pharmaron's service portfolio supports diverse modalities, including small molecules, biologics, and advanced therapeutics such as cell and gene therapy (CGT) products. It partners with pharmaceutical, biotechnology, and medical device companies globally to advance their R&D pipelines.

Recent filings

Filing Released Lang Actions
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2024-06-17 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2024-06-06 English
(UPDATED) FINAL DIVIDEND IN CASH FOR THE YEAR ENDED DECEMBER 31, 2023
Notice of Dividend Amount Classification · 100% confidence The document is titled as a 'Cash Dividend Announcement' for the year ended December 31, 2023, and provides detailed information about the dividend amount, payment dates, withholding tax information, and shareholder register details. It is an announcement regarding the dividend payment rather than a full financial report or annual report. The document length is 7354 characters, which is sufficient for a detailed announcement but it does not contain comprehensive financial statements or management discussion. The content focuses on dividend declaration and payment logistics, which fits the category of Notice of Dividend Amount (DIV).
2024-06-06 English
Articles of Association
Governance Information Classification · 95% confidence The document is titled 'Articles of Association' for Pharmaron Beijing Co., Ltd. It includes detailed chapters on company governance, share issuance, shareholders' meetings, board of directors, senior management, supervisory committee, financial and accounting systems, and other corporate governance matters. The document references approval at the Annual General Meeting and class meetings in 2024. The content is a comprehensive legal and governance framework document for the company, not a financial report or announcement. This type of document fits the definition of Governance Information (CGR), which covers the company's internal rules, board structure, and governance practices. The document length is substantial (15,000 characters), indicating it is the full Articles of Association, not a brief announcement or summary. Therefore, the correct classification is CGR with high confidence.
2024-06-06 English
(I) POLL RESULTS OF THE ANNUAL GENERAL MEETING OF 2023, THE FIRST A SHARE CLASS MEETING OF 2024 AND THE FIRST H SHARE CLASS MEETING OF 2024 HELD ON JUNE 6, 2024&#x3b; (II) THE 2023 PROFIT DISTRIBUTION
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement from Pharmaron Beijing Co., Ltd. regarding the poll results of the Annual General Meeting (AGM) of 2023, the first A Share Class Meeting of 2024, and the first H Share Class Meeting of 2024 held on June 6, 2024. It includes detailed voting results on various resolutions, including the 2023 profit distribution plan and amendments to the articles of association. The document also discusses dividend distribution details. The content is focused on the official results of shareholder votes at these meetings, which aligns with the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document is lengthy and detailed, not merely a brief announcement or a report publication notice, and it does not contain full financial statements or management discussion, so it is not an Annual Report or Interim Report. It is not a proxy solicitation or investor presentation. Therefore, the correct classification is DVA with high confidence.
2024-06-06 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2024-06-05 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.